(vox.com)

With mRNA vaccines, the science of an update to the latest “variant of concern” is probably the easy part. That’s one of the major benefits of the technology over old-school vaccines. But, in the midst of a pandemic, limited regulatory review resources and manufacturing capacity are powerful forces for holding off on new versions…for now.